HIV Patients' Immune Response to Hepatitis B Vaccine
Author Information
Author(s): Pasricha Neelam, Datta Usha, Chawla Yogesh, Singh Surjit, Arora Sunil K, Sud Archana, Minz Ranjana W, Saikia Biman, Singh Haqeeqat, James Isaac, Sehgal Shobha
Primary Institution: Post Graduate Institute of Medical Education and Research, Chandigarh, India
Hypothesis
The study aims to assess the efficacy of recombinant Hepatitis B virus vaccine in treatment-naive HIV positive patients compared to healthy controls.
Conclusion
Vaccination in HIV positive patients with low CD4+ lymphocytes was ineffective, highlighting the need for early immunization in these patients.
Supporting Evidence
- CD4+, CD8+, and CD3+ cells increased significantly in all groups after vaccination.
- HBsAb levels were significantly lower in HIV positive patients compared to controls.
- Vaccination was ineffective in patients with CD4+ lymphocytes < 50/mm3.
Takeaway
HIV patients may not respond well to the Hepatitis B vaccine, especially if their immune system is weak, so it's better to vaccinate them early.
Methodology
Forty HIV positive patients and 20 HIV negative controls were vaccinated with three doses of the Hepatitis B vaccine, and immune responses were assessed using flow cytometry and ELISA.
Potential Biases
Potential selection bias in recruiting HIV positive patients who could not afford HAART.
Limitations
The study may not be generalizable to all populations due to geographical and genetic differences.
Participant Demographics
40 HIV positive patients (17 males, 10 females, mean age 30) and 20 healthy controls (12 males, 8 females, mean age 29).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website